Eikonizo therapeutics secures investment from Novo Nordisk for EKZ-102 development
- Eikonizo Therapeutics received an undisclosed equity investment from Novo Nordisk to advance its lead candidate, EKZ-102.
- EKZ-102 is a first-in-class, oral, CNS-penetrant HDAC6 inhibitor aimed at treating ALS and other neurodegenerative diseases.
- The investment will also support the development of novel HDAC6 inhibitors for cardiorenal diseases.
- A first-in-human clinical study for EKZ-102 is planned for 2025.
Read more
Wavegate Corporation secures $26 million in Series A funding
- Wavegate Corporation raised $26 million in Series A funding led by UCEA Capital Partners Ltd.
- The funding will accelerate the development of Wavegate's Ellipse platform with StimuLux technology for chronic pain management.
- Ellipse platform uses optical reflectometry for real-time adaptive modulation, offering consistent pain relief.
- The investment will support R&D, clinical trials, and regulatory preparations for commercialization.
Read more
Noema Pharma extends Series B financing round, closing at CHF 130 Million ($147 Million)
- Noema Pharma closed a Series B extension financing round, raising CHF 130 million (USD 147 million).
- EQT Life Sciences joined previous investors like Forbion and Jeito Capital in this round.
- Funds will support four active Phase 2 trials, with data readouts expected in 2025.
- Key trials include basimglurant for trigeminal neuralgia and seizures, and gemlapodect for Tourette syndrome.
Read more
